TS
MLYS icon

Thomas Steyer’s Mineralys Therapeutics MLYS Stock Holding History

Thomas Steyer’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-823,296
Closed -$29.9M – 192
2025
Q4 		$29.9M Sell
823,296
-849,757
-51% -$34.1M 0.13% 64
2025
Q3 		$63.4M Buy
+1,673,053
New +$36.2M 0.26% 54

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $229M AUM 100.3% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return

Thomas Steyer's MLYS Position: Q1 2026 in Review

Thomas Steyer sold out of Mineralys Therapeutics (MLYS) in Q1 2026, closing a stake of 823,296 shares — an estimated $29.9M sold.

Thomas Steyer first reported a position in MLYS in Q3 2025 and held it in 2 quarters. The position peaked at $63.4M in Q3 2025. 214 funds tracked by Wall St. Rank hold MLYS as of Q1 2026.

  • Thomas Steyer reported no remaining Mineralys Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Thomas Steyer sold 823,296 Mineralys Therapeutics shares in Q1 2026, an estimated $29.9M.
  • Thomas Steyer first reported a position in Mineralys Therapeutics in Q3 2025 and held it in 2 quarters.
  • Thomas Steyer's Mineralys Therapeutics position peaked at $63.4M in Q3 2025.
  • 214 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q1 2026.

Based on Farallon Capital Management's 13F filing for Q1 2026, filed 15 May 2026.